50% off all subscriptions! ... left. Order NowOrder Now

Enanta Pharmaceuticals Stock Forecast NASDAQ:ENTA

$91.89 (5.75%)

Volume: 357k

Closed: Nov 26, 2021

Hollow Logo Score: 3.651

Enanta Pharmaceuticals Stock Forecast

$91.89 (5.75%)

Volume: 357k

Closed: Nov 26, 2021

Score Hollow Logo 3.651
Which way will ENTA go? Request
Stop-loss: $87.48 (-4.80%)
Key Stats
P/E Ratio -22.30
Beta 0.65
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 44 and the stock is currently not being overbought or oversold

Strong day for Enanta Pharmaceuticals stock price on Friday rising 5.75% to $91.89
(Updated on Nov 26, 2021)


Buy candidate since 2021-11-23 Gain 6.23%

The Enanta Pharmaceuticals stock price gained 5.75% on the last trading day (Friday, 26th Nov 2021), rising from $86.89 to $91.89. , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 7.97% from a day low at $86.04 to a day high of $92.90. The price has risen in 7 of the last 10 days and is up by 1% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 153 thousand more shares were traded than the day before. In total, 357 thousand shares were bought and sold for approximately $32.78 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 67.84% during the next 3 months and, with a 90% probability hold a price between $129.64 and $179.55 at the end of this 3-month period.

Signals & Forecast

The Enanta Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $85.80 and $81.98. A breakdown below any of these levels will issue sell signals. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Friday, November 05, 2021, and so far it has fallen -5.63%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss

On the downside, the stock finds support just below today's level from accumulated volume at $86.50 and $85.85. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Enanta Pharmaceuticals finds support just below today's level at $86.50. If this is broken, then the next support from accumulated volume will be at $85.85 and $75.33.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $6.86 between high and low, or 7.97%. For the last week, the stock has had a daily average volatility of 10.44%.

Our recommended stop-loss: $87.48 (-4.80%) (This stock has high daily movements and this gives high risk. There is a sell signal from a pivot top found 14 days ago.)

Is Enanta Pharmaceuticals stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Enanta Pharmaceuticals stock to perform well in the short-term.

Current score: 3.651

Predicted Opening Price for Enanta Pharmaceuticals of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$90.28 $91.89 (Overvalued)
Buy Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 24, 2021 "Oppenheimer" gave "$55.00 - $73.00" rating for ENTA. The price target was set to $86.76+0.3%.

Volatility and Risk
Daily Average Volatility: 10.44 %
Overall Risk: Very High High Medium Low Very Low
Volatility
10.44 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $92.21
Price: $91.89
Support: $86.50

ENTA Insider Trading Show all Trades

INSIDER POWER

7.490

Last 100 transactions
Buy: 1 002 843 | Sell: 133 896 (Shares)
Date Action Amount Person Type
Nov 19, 2021 Buy 28 400 Luu Brendan Stock Option (right to buy)
Nov 19, 2021 Buy 6 800 Luu Brendan Common Stock
Nov 19, 2021 Buy 28 400 Kieffer Tara Lynn Stock Option (right to buy)
Nov 19, 2021 Buy 6 800 Kieffer Tara Lynn Common Stock
Nov 19, 2021 Buy 28 400 Gardiner Nathaniel S. Stock Option (right to buy)
Show all Insider Trades
INSIDER POWER

7.490

Last 100 transactions
Buy: 1 002 843 | Sell: 133 896 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 97.14 5.71 %
94.52 2.86 %
92.90 1.10 %
Current price: 91.89
Support 87.66 -4.61 %
86.04 -6.37 %
83.42 -9.22 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 97.37 5.96 %
94.24 2.56 %
92.21 0.35 %
Current price 91.89
Support 86.50 -5.87%
85.85 -6.57%
75.33 -18.02%

Click to get the best stock tips daily for free!

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease i... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT